Adequate levofloxacin treatment schedules for uterine cervicitis caused by Chlamydia trachomatis

Chemotherapy. 2000 Mar-Apr;46(2):150-2. doi: 10.1159/000007270.

Abstract

The in vivo efficacy of levofloxacin (LVFX), one of the most standard new quinolone antimicrobial agents, in the different treatment schedules of Chlamydia trachomatis uterine cervicitis in women was evaluated. Cervical C. trachomatis was detected by polymerase chain reaction. LVFX at a dosage of 300 mg t.i.d. for 5, 7 and 14 days was orally administered to 18, 33 and 35 Japanese patients, respectively. The eradication rate and the recurrence rate in the different treatment schedules of C. trachomatis were evaluated. The eradication rate in 5-, 7- or 14-day cases was 44.4, 87.9 or 88.6%, respectively. The recurrence rate of 5-, 7- or 14-day cases was 50.0, 0 or 0%, respectively. Seven-day treatment with LVFX is adequate for and effective in C. trachomatis uterine cervicitis.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Chlamydia Infections / drug therapy*
  • Chlamydia trachomatis / drug effects*
  • Drug Administration Schedule
  • Female
  • Humans
  • Levofloxacin*
  • Middle Aged
  • Ofloxacin / administration & dosage*
  • Ofloxacin / adverse effects
  • Ofloxacin / therapeutic use*
  • Recurrence
  • Time Factors
  • Uterine Cervicitis / drug therapy*
  • Uterine Cervicitis / microbiology

Substances

  • Levofloxacin
  • Ofloxacin